Treatments Targeting MDS Genetics: a Fool's Errand?

Overview

Journal Hematology Am Soc Hematol Educ Program

Specialty Hematology

Date 2018 Dec 4

PMID 30504322

Citations 4

Authors

Amy E DeZern

Affiliations

Soon will be listed here.

Abstract

The myelodysplastic syndromes are collectively the most common myeloid neoplasms. Clonal hematopoiesis present in these diseases results in bone marrow failure characteristically seen in patients. The heterogeneity of myelodysplastic syndrome pathobiology has historically posed a challenge to the development of newer therapies. Recent advances in molecular characterization of myelodysplastic syndromes are improving diagnostic accuracy, providing insights into pathogenesis, and refining therapeutic options for patients. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.

Citing Articles

Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.

Hochman M, Muniz J, Papadantonakis N J Pers Med. 2025; 15(2).

PMID: 39997326 PMC: 11856194. DOI: 10.3390/jpm15020049.

Defining the mutational profile of lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing.

Adamska M, Kowal-Wisniewska E, Czerwinska-Rybak J, Kiwerska K, Baranska M, Gronowska W Contemp Oncol (Pozn). 2024; 27(4):269-279.

PMID: 38405213 PMC: 10883195. DOI: 10.5114/wo.2023.135365.

The Coming of Age of Preclinical Models of MDS.

Liu W, Teodorescu P, Halene S, Ghiaur G Front Oncol. 2022; 12:815037.

PMID: 35372085 PMC: 8966105. DOI: 10.3389/fonc.2022.815037.

Lower risk but high risk.

DeZern A Hematology Am Soc Hematol Educ Program. 2021; 2021(1):428-434.

PMID: 34889376 PMC: 8791100. DOI: 10.1182/hematology.2021000277.

Prognostic Markers of Myelodysplastic Syndromes.

Veryaskina Y, Titov S, Kovynev I, Pospelova T, Zhimulev I Medicina (Kaunas). 2020; 56(8).

PMID: 32727068 PMC: 7466347. DOI: 10.3390/medicina56080376.

References

Hientz K, Mohr A, Bhakta-Guha D, Efferth T . The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2016; 8(5):8921-8946. PMC: 5352454. DOI: 10.18632/oncotarget.13475. View

Russler-Germain D, Spencer D, Young M, Lamprecht T, Miller C, Fulton R . The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014; 25(4):442-54. PMC: 4018976. DOI: 10.1016/j.ccr.2014.02.010. View

Ley T, Ding L, Walter M, McLellan M, Lamprecht T, Larson D . DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363(25):2424-33. PMC: 3201818. DOI: 10.1056/NEJMoa1005143. View

Lindsley R, Mar B, Mazzola E, Grauman P, Shareef S, Allen S . Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9):1367-76. PMC: 4342352. DOI: 10.1182/blood-2014-11-610543. View

Chang C, Zhao Y, Xu F, Guo J, Zhang Z, He Q . TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol. 2016; 176(4):600-608. DOI: 10.1111/bjh.14455. View

Della Porta M, Galli A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E . Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2016; 34(30):3627-3637. PMC: 6366344. DOI: 10.1200/JCO.2016.67.3616. View

Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N . Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J Clin Oncol. 2016; 34(25):2988-96. DOI: 10.1200/JCO.2015.66.0118. View

Kulasekararaj A, Smith A, Mian S, Mohamedali A, Krishnamurthy P, Lea N . TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013; 160(5):660-72. DOI: 10.1111/bjh.12203. View

Heuser M, Gabdoulline R, Loffeld P, Dobbernack V, Kreimeyer H, Pankratz M . Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Ann Hematol. 2017; 96(8):1361-1372. PMC: 7116654. DOI: 10.1007/s00277-017-3027-5. View

10.

Stein E, DiNardo C, Pollyea D, Fathi A, Roboz G, Altman J . Enasidenib in mutant relapsed or refractory acute myeloid leukemia. Blood. 2017; 130(6):722-731. PMC: 5572791. DOI: 10.1182/blood-2017-04-779405. View

11.

DiNardo C, Stein E, de Botton S, Roboz G, Altman J, Mims A . Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018; 378(25):2386-2398. DOI: 10.1056/NEJMoa1716984. View

12.

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G . Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-506. PMC: 3159042. DOI: 10.1056/NEJMoa1013343. View

13.

Kronke J, Fink E, Hollenbach P, MacBeth K, Hurst S, Udeshi N . Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015; 523(7559):183-188. PMC: 4853910. DOI: 10.1038/nature14610. View

14.

Bejar R, Stevenson K, Caughey B, Lindsley R, Mar B, Stojanov P . Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014; 32(25):2691-8. PMC: 4207878. DOI: 10.1200/JCO.2013.52.3381. View

15.

Lindsley R, Saber W, Mar B, Redd R, Wang T, Haagenson M . Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017; 376(6):536-547. PMC: 5438571. DOI: 10.1056/NEJMoa1611604. View

16.

Spivak J . Myeloproliferative Neoplasms. N Engl J Med. 2017; 377(9):895-6. DOI: 10.1056/NEJMc1708485. View

17.

Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Galli A, Della Porta M . Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014; 124(9):1513-21. PMC: 4148773. DOI: 10.1182/blood-2014-03-560227. View

18.

Yang H, Kurtenbach S, Guo Y, Lohse I, Durante M, Li J . Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Blood. 2017; 131(3):328-341. PMC: 5774208. DOI: 10.1182/blood-2017-06-789669. View

19.

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P . Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616-27. PMC: 3837510. DOI: 10.1182/blood-2013-08-518886. View

20.

Uy G, Duncavage E, Chang G, Jacoby M, Miller C, Shao J . Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. 2016; 31(4):872-881. PMC: 5382101. DOI: 10.1038/leu.2016.282. View